Your browser doesn't support javascript.
loading
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.
Zhou, Tongqing; Teng, I-Ting; Olia, Adam S; Cerutti, Gabriele; Gorman, Jason; Nazzari, Alexandra; Shi, Wei; Tsybovsky, Yaroslav; Wang, Lingshu; Wang, Shuishu; Zhang, Baoshan; Zhang, Yi; Katsamba, Phinikoula S; Petrova, Yuliya; Banach, Bailey B; Fahad, Ahmed S; Liu, Lihong; Lopez Acevedo, Sheila N; Madan, Bharat; de Souza, Matheus Oliveira; Pan, Xiaoli; Wang, Pengfei; Wolfe, Jacy R; Yin, Michael; Ho, David D; Phung, Emily; DiPiazza, Anthony; Chang, Lauren; Abiona, Olubukula; Corbett, Kizzmekia S; DeKosky, Brandon J; Graham, Barney S; Mascola, John R; Misasi, John; Ruckwardt, Tracy; Sullivan, Nancy J; Shapiro, Lawrence; Kwong, Peter D.
Afiliação
  • Zhou T; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Teng IT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Olia AS; These authors contributed equally.
  • Cerutti G; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Gorman J; These authors contributed equally.
  • Nazzari A; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA.
  • Shi W; These authors contributed equally.
  • Tsybovsky Y; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Wang L; These authors contributed equally.
  • Wang S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Zhang B; These authors contributed equally.
  • Zhang Y; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Katsamba PS; Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
  • Petrova Y; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Banach BB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Fahad AS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Liu L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Lopez Acevedo SN; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA.
  • Madan B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • de Souza MO; Bioengineering Graduate Program, The University of Kansas, Lawrence, KS 66045, USA.
  • Pan X; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045, USA.
  • Wang P; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Wolfe JR; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045, USA.
  • Yin M; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045, USA.
  • Ho DD; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045, USA.
  • Phung E; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045, USA.
  • DiPiazza A; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Chang L; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045, USA.
  • Abiona O; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Corbett KS; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • DeKosky BJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Misasi J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Ruckwardt T; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Sullivan NJ; Bioengineering Graduate Program, The University of Kansas, Lawrence, KS 66045, USA.
  • Shapiro L; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045, USA.
  • Kwong PD; Department of Chemical Engineering, The University of Kansas, Lawrence, KS 66045, USA.
bioRxiv ; 2020 Jun 23.
Article em En | MEDLINE | ID: mdl-32596696
Biotin-labeled molecular probes, comprising specific regions of the SARS-CoV-2 spike, would be helpful in the isolation and characterization of antibodies targeting this recently emerged pathogen. To develop such probes, we designed constructs incorporating an N-terminal purification tag, a site-specific protease-cleavage site, the probe region of interest, and a C-terminal sequence targeted by biotin ligase. Probe regions included full-length spike ectodomain as well as various subregions, and we also designed mutants to eliminate recognition of the ACE2 receptor. Yields of biotin-labeled probes from transient transfection ranged from ~0.5 mg/L for the complete ectodomain to >5 mg/L for several subregions. Probes were characterized for antigenicity and ACE2 recognition, and the structure of the spike ectodomain probe was determined by cryo-electron microscopy. We also characterized antibody-binding specificities and cell-sorting capabilities of the biotinylated probes. Altogether, structure-based design coupled to efficient purification and biotinylation processes can thus enable streamlined development of SARS-CoV-2 spike-ectodomain probes.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article